Iterum Therapeutics Confirms Nasdaq Delisting and Ceases SEC Filings Following Winding-Up Petition
ITRM has more than doubled off its 52-week low of $0.027 on elevated volume (52× avg).
Summary
Iterum Therapeutics plc announced its shares will be delisted from Nasdaq on April 1, 2026, and it will cease all SEC filings, confirming the final stages of its winding-up process.
Key Events · Legal and Risk Events · ITRM
-
Nasdaq Delisting Confirmed
The company withdrew its appeal against Nasdaq's delisting determination, leading to the suspension of trading on April 1, 2026, and removal from the exchange.
-
Cessation of SEC Filings
Iterum Therapeutics announced it will no longer file reports with the SEC, including its 2025 Annual Report on Form 10-K, due to its winding-up process and limited cash.
-
Follows Winding-Up Petition
This delisting and cessation of filings are direct consequences of the company's petition to wind up in Ireland, as disclosed on March 27, 2026.
Analysis · ITRM · Life Sciences
This 8-K filing provides critical updates following the company's previously announced petition to wind up. The withdrawal of its appeal against Nasdaq's delisting determination confirms that trading of its ordinary shares will be suspended on April 1, 2026, effectively ending its public listing. Furthermore, the company explicitly states it will cease all future SEC filings, including its Annual Report on Form 10-K, due to limited cash and the ongoing winding-up process. This marks the definitive end of Iterum Therapeutics as a publicly traded and reporting entity, solidifying the complete loss of liquidity for shareholders on Nasdaq.
At the time of this filing, ITRM was trading at $0.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.03 to $1.42. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.